Oncology/Hematology
Other Cancers
More in Other Cancers
More than 40% of adults, half of children met response criteria, majority of responses durable
Nov 15, 2024
But absence of significant OS benefit raises questions about long-term benefit, expert says
Nov 13, 2024
Delegates express concerns that PPE doesn't always cover women, who are more at risk of exposure
Nov 12, 2024
And nearly half of responders to enfortumab vedotin plus pembrolizumab remained in remission
Nov 08, 2024